Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Brand-name prescription medicine

Rytary

Generic name: Carbidopa and levodopa

FDA application holder: Impax

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Rytary?
Rytary is a brand name of Carbidopa and levodopa, a prescription medicine. The FDA NDC Directory lists 4 Rytary products in 4 strengths and forms.
Who makes Rytary?
Impax holds the FDA application for Rytary (NDA203312, approved January 7, 2015).
Is there a generic or store brand of Rytary?
Other products of Carbidopa and levodopa are listed with the FDA, but none in exactly the same strength and form as a Rytary product.
What do pharmacies pay for Rytary?
CMS lists a National Average Drug Acquisition Cost (NADAC) for 4 Rytary strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
Has Rytary been recalled?
No recall linked to Rytary products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Rytary is

Each Rytary product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Carbidopa and levodopa · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
carbidopa hydrate 23.75 mg · levodopa 95 mg
capsule, extended release (oral)
Rytary None listed DailyMed
carbidopa hydrate 36.25 mg · levodopa 145 mg
capsule, extended release (oral)
Rytary None listed DailyMed
carbidopa hydrate 48.75 mg · levodopa 195 mg
capsule, extended release (oral)
Rytary None listed DailyMed
carbidopa hydrate 61.25 mg · levodopa 245 mg
capsule, extended release (oral)
Rytary None listed DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Carbidopa and levodopa →

FDA approval

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
FDA applications of Rytary products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
NDA203312ImpaxJanuary 7, 20154

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Rytary, by strength and form
Strength and formGeneric or brandPharmacies pay
carbidopa hydrate 23.75 mg · levodopa 95 mg
capsule, extended release
Brand: Rytary $3.98 per capsule
carbidopa hydrate 36.25 mg · levodopa 145 mg
capsule, extended release
Brand: Rytary $3.97 per capsule
carbidopa hydrate 48.75 mg · levodopa 195 mg
capsule, extended release
Brand: Rytary $3.98 per capsule
carbidopa hydrate 61.25 mg · levodopa 245 mg
capsule, extended release
Brand: Rytary $5.00 per capsule

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list Rytary

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Rytary products.

Recalls

No recall linked to Rytary products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers